API A4 Alzheimer's Prevention Trial — Paul S. Aisen (BANNER HEALTH)
Project Summary/Abstract There is an urgent need to find and accelerate approval of Alzheimer’s disease (AD) prevention therapies. Aducanumab is an antibody that binds selectively to amyloid-β (Aβ) ol
| Project title | API A4 Alzheimer's Prevention Trial |
|---|---|
| Project number | 5R01AG058468-02 |
| PI name | Paul S. Aisen |
| Institution | BANNER HEALTH |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $7.16M |
| Fiscal year | 2021 |
| Project start | 2018-09-01T00:00:00 |
| Project end | 2024-11-30T00:00:00 |
| Abstract | Project Summary/Abstract There is an urgent need to find and accelerate approval of Alzheimer’s disease (AD) prevention therapies. Aducanumab is an antibody that binds selectively to amyloid-β (Aβ) ol |
| Key terms | <AD dementia><AD prevention><Abscission><Address><Aducanumab><Affect><Affective><Alleles><Allelomorp |
$799/mo
Try GrantRadar →